Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Mariana Oncology Inc.
Headquarters: Cambridge, Massachusetts, United States of America
Website: N/A
Year Founded: 2020
Status: Acquired
BioCentury | Feb 4, 2025
Finance
Australian radiopharma play Advancell taps VCs for $112M in ‘scale capital’
Expanding in U.S., the biotech will build manufacturing capacity for α-emitters, including clinical program for prostate cancer
BioCentury | Oct 15, 2024
Finance
Forbion’s European capital wave
Sticking to its strategy, firm raises $2.2B just 18 months after raising $1.5B
BioCentury | Sep 17, 2024
Finance
Why radiopharma Pentixapharm chose Frankfurt for IPO
Eckert & Ziegler spinout aiming for 4Q24 debut with secondary listing as future option
BioCentury | Jul 22, 2024
Product Development
Battle of the alphas: lead-212 picks up speed in radiopharma
The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale
BioCentury | Jun 5, 2024
Management Tracks
Sanofi vet Frank Nestle joins Deerfield as partner, CEO of 3DC
Plus: Lilly CFO Anat Ashkenazi leaving for Alphabet, and updates from Y-mAbs, Danaher and more
BioCentury | May 7, 2024
Deals
Deals report: Novartis strengthens radiotherapy pipeline with pair of deals
Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more
BioCentury | May 2, 2024
Deals
Novartis gains α-emitter, radioligand platform via $1B Mariana takeout
Largest upfront M&A payment for a preclinical biotech in three years
BioCentury | Dec 1, 2023
Product Development
Radiopharmaceuticals’ multi-dimensional next wave
Target, ligand and radioisotope choices fuel the growing field
BioCentury | Oct 3, 2023
Deals
Lilly’s big step into radiopharma comes via $1.4B Point takeout
Looking beyond partnered programs, pharma acquires supply and manufacturing capabilities along with wholly-owned radioligand pipeline
BioCentury | Sep 8, 2023
Deals
Sept. 7 Quick Takes: Seagen, Nurix in deal to create degrader-antibody conjugates
Plus: U.K. rejoins Horizon Europe and more from Mariana, Corteria, Noetik, CymaBay, J&J, Alnylam and BlueWhale
Items per page:
1 - 10 of 12